Catalyst Pharmaceutical Partners, Inc.

Form 4

October 22, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

0.5

Check this box if no longer

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

January 31, Expires: 2005

OMB APPROVAL

subject to Section 16. Form 4 or

SECURITIES

Estimated average burden hours per response...

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

Miller Steve

2. Issuer Name and Ticker or Trading

Symbol

Catalyst Pharmaceutical Partners,

(Month/Day/Year)

5. Relationship of Reporting Person(s) to

Issuer

Inc. [CPRX]

10/20/2009

(Last) (First) (Middle) 3. Date of Earliest Transaction

Director 10% Owner X_ Officer (give title Other (specify

(Check all applicable)

below)

VP Development & Management

355 ALHAMBRA CIRCLE, SUITE

(Street)

(State)

1370

(Instr. 3)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

CORAL GABLES, FL 33134

(City) 1. Title of 2. Transaction Date 2A. Deemed Security

(Month/Day/Year) Execution Date, if

(Month/Day/Year)

(Zip)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 3, 4 and 5) (Instr. 8)

5. Amount of Securities Beneficially Owned Following Reported

6. Ownership Form: Direct (I) (Instr. 4)

7. Nature of Indirect (D) or Indirect Beneficial Ownership (Instr. 4)

(A) or

Transaction(s) (Instr. 3 and 4)

Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

3. Transaction Date 3A. Deemed 1. Title of Conversion

5. Number of (Month/Day/Year) Execution Date, if TransactionDerivative Securities

Date Exercisable and **Expiration Date**

7. Title and Amo Underlying Secu

Edgar Filing: Catalyst Pharmaceutical Partners, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Am Nu Sha
Options to purchase common stock	\$ 3.6	10/20/2009		H <u>(1)</u>		100,000	<u>(2)</u>	04/04/2012	Common Stock	10
Options to purchase common stock	\$ 0.9	10/20/2009		A	58,333		10/20/2009	10/20/2014	Common Stock	58
Options to purchase common stock	\$ 0.9	10/20/2009		A	58,333		10/20/2010	10/20/2014	Common Stock	5
Options to purchase common stock	\$ 0.9	10/20/2009		A	58,334		10/20/2011	10/20/2014	Common Stock	58

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Miller Steve

355 ALHAMBRA CIRCLE SUITE 1370

VP Development & Management

CORAL GABLES, FL 33134

Signatures

/s/ Steven Miller 10/22/2009

**Signature of Pate Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options were cancelled pursuant to the above-described grant.
- (2) 1/3 of such shares vested on April 4, 2007; 1/3 of such shares vested on April 4, 2008; and 1/3 of such shares vested on April 4, 2009.

Reporting Owners 2

Edgar Filing: Catalyst Pharmaceutical Partners, Inc. - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.